Last updated on August 2016

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD


Brief description of study

This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular age-related macular degeneration (NVAMD).

Detailed Study Description

Evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple doses of RXI-109 when administered by intravitreal injection. Evaluate the clinical activity of single and multiple doses of RXI-109 when administered by intravitreal injection. Study participation is intended to be seven months from time of initial treatment with RXI-109.

Clinical Study Identifier: NCT02599064

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Clinical Trials Manager

Wilmer Eye Institute at Johns Hopkins
Baltimore, MD United States
  Connect »